Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

被引：0
|
作者：
Axel Heidenreich
Silke Gillessen
Daniel Heinrich
Daniel Keizman
Joe M. O’Sullivan
Joan Carles
Manfred Wirth
Kurt Miller
John Reeves
Monica Seger
Sten Nilsson
Fred Saad
机构：
[1] University Hospital Cologne,Department of Urology
[2] Division of Cancer Sciences,Department of Oncology
[3] University of Manchester and the Christie,Department of Medical Oncology
[4] Medical Oncology and Haematology,Department of Urology
[5] Kantonsspital St Gallen,Department of Urology
[6] University of Bern,Department of Oncology
[7] Akershus University Hospital,Department of Urology
[8] Genitourinary Oncology Service,undefined
[9] Institute of Oncology,undefined
[10] Meir Medical Center,undefined
[11] Department of Clinical Oncology,undefined
[12] The Centre for Cancer Research and Cell Biology,undefined
[13] Queen’s University Belfast and the Northern Ireland Cancer Centre,undefined
[14] Vall d’Hebron University Hospital,undefined
[15] Vall d’Hebron Institute of Oncology,undefined
[16] University Hospital Carl-Gustav Carus,undefined
[17] Charité University Medicine Berlin,undefined
[18] Pharmaceutical Division of Bayer,undefined
[19] Karolinska University Hospital,undefined
[20] Centre Hospitalier de l’Université de Montréal (CHUM),undefined
来源：
BMC Cancer | / 19卷
关键词：
Radium-223; mCRPC, asymptomatic; Symptomatic; Bone metastases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Evaluation of Radium-223 Dichloride in the Treatment of Castration-Resistant Prostate Adenocarcinoma with Symptomatic Bone Metastases
    Maestre-Cutillas, R.
    Sanchez-Tornero, A. M.
    Baz-Sanz, L.
    Rubio-Fernandez, G.
    Casas-Fernandez, L.
    Romero-Otero, M.
    Perez-Iruela, J. A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S652 - S652
  • [32] Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database
    D Keizman
    M O Fosboel
    H Reichegger
    A Peer
    E Rosenbaum
    M-C Desax
    V Neiman
    P M Petersen
    J Mueller
    R Cathomas
    M Gottfried
    H Dresler
    D Sarid
    W Mermershtain
    K Rouvinov
    J Mortensen
    S Gillessen
    G Daugaard
    A Omlin
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 289 - 293
  • [33] Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
    Vidal, Monica
    Delgado, Alejandro
    Martinez, Carlos
    Jaime Correa, Jose
    Cristina Durango, Isabel
    INTERNATIONAL BRAZ J UROL, 2020, 46 (04): : 599 - 611
  • [34] Treatment outcome of radium-223 treatment for castration-resistant prostate cancer and bone metastases at a single university hospital
    Takayama, T.
    Sugihara, T.
    Kameda, T.
    Yamazaki, M.
    Komatsubara, M.
    Kamei, J.
    Fujisaki, A.
    Ando, S.
    Fujimura, T.
    INTERNATIONAL JOURNAL OF RADIATION RESEARCH, 2022, 20 (01): : 75 - 81
  • [35] Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
    Yamamoto, Yoshiyuki
    Okuda, Yohei
    Kanaki, Tomohiro
    Tanaka, Ryo
    Nagahara, Akira
    Nakai, Yasutomo
    Nakayama, Masashi
    Kakimoto, Ken-ichi
    Nishimura, Kazuo
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 192 - 198
  • [36] The impact of genetic mutations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Liu, Alex John
    Kosiorek, Heidi E.
    Ueberroth, Benjamin Edward
    Kendi, Ayse T.
    Tzou, Katherine S.
    Quevedo, Fernando
    Choo, Richard
    Moore, Cassandra N.
    Ho, Thai Huu
    Singh, Parminder
    Keole, Sameer R.
    Wong, William
    Bryce, Alan Haruo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223
    Parker, C.
    O'Bryan-Tear, C. G.
    Bolstad, B.
    Lokna, A.
    Nilsson, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [38] Radium-223 systemic alpha-radiotherapy: targeted treatment of castration-resistant prostate cancer with bone metastases
    Volkova, M., I
    Olshanskaya, A. S.
    ONKOUROLOGIYA, 2019, 15 (02): : 134 - 142
  • [39] Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer
    Buroni, Federica Eleonora
    Persico, Marco Giovanni
    Pasi, Francesca
    Lodola, Lorenzo
    Nano, Rosanna
    Aprile, Carlo
    ANTICANCER RESEARCH, 2016, 36 (11) : 5719 - 5730
  • [40] Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases
    Yoshiyuki Yamamoto
    Yohei Okuda
    Tomohiro Kanaki
    Ryo Tanaka
    Akira Nagahara
    Yasutomo Nakai
    Masashi Nakayama
    Ken-ichi Kakimoto
    Kazuo Nishimura
    International Journal of Clinical Oncology, 2021, 26 : 192 - 198
12345